Myriad Genetics, Inc. (MYGN)
$4.20-2.55%Close
BUYRECOVERY · day 31
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $397M
- Beta
- 1.68
- P/E (TTM)
- -3.58
- Short % float
- 9.94%
- Days to cover
- 4.3
- SI change
- -8.6%
- 1W
- -8.30%
- 1M
- +22.81%
- vs SPY 1W
- -8.72%
- vs SPY 1M
- +20.75%
Industry peers
FMP comparable companies · ranked by market cap
- NTRABUYNatera, Inc.$56.7BBULLQ 30$395.65-0.73%
- GHSELLGuardant Health, Inc.$21.8BCRISISQ 23$162.09-2.79%
- QGENBUYQiagen N.V.$9.4BRECOVERYQ 16$45.44-0.15%
- BLLNSELLBillionToOne, Inc.$4.3BCRISISQ -10$94.44-5.12%
- VCYTBUYVeracyte, Inc.$3.4BBEARQ 14$43.11-2.68%
- PSNLSELLPersonalis, Inc.$1.7BBEARQ 6$15.85-1.25%
- FLGTBUYFulgent Genetics, Inc.$598MRECOVERYQ 13$21.06-1.24%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on MYGN?
- LOPJLB’s latest quantitative signal on Myriad Genetics, Inc. (MYGN) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is MYGN in?
- Myriad Genetics, Inc. (MYGN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Myriad Genetics, Inc. (MYGN) do?
- Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, womenâs health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, …